Mass cytometry of Hodgkin lymphoma reveals a CD4+ regulatory T-cell-rich and exhausted T-effector microenvironment

被引:140
作者
Cader, Fathima Zumla [1 ]
Schackmann, Ron C. J. [2 ]
Hu, Xihao [3 ,4 ]
Wienand, Kirsty [1 ]
Redd, Robert [3 ,4 ]
Chapuy, Bjoern [1 ]
Ouyang, Jing [1 ]
Paul, Nicole [5 ]
Gjini, Evisa [6 ]
Lipschitz, Mikel [6 ]
Armand, Philippe [1 ]
Wu, David [7 ]
Fromm, Jonathan R. [7 ]
Neuberg, Donna [3 ,4 ]
Liu, X. Shirley [3 ,4 ]
Rodig, Scott J. [6 ]
Shipp, Margaret A. [1 ]
机构
[1] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA
[2] Harvard Med Sch, Dept Cell Biol, Boston, MA USA
[3] Dana Farber Canc Inst, Dept Biostat & Computat Biol, Boston, MA 02115 USA
[4] Harvard TH Chan Sch Publ Hlth, Boston, MA USA
[5] Dana Farber Canc Inst, Longwood Med Area CyTOF Core Facil, Boston, MA 02115 USA
[6] Brigham & Womens Hosp, Dept Pathol, 75 Francis St, Boston, MA 02115 USA
[7] Univ Washington, Dept Pathol, Seattle, WA 98195 USA
基金
美国国家卫生研究院;
关键词
REED-STERNBERG CELLS; CLASS-I EXPRESSION; HLA-CLASS-I; IMMUNE EVASION; FLOW-CYTOMETRY; PD-1; BLOCKADE; PHASE-II; NK CELLS; PHENOTYPE; MELANOMA;
D O I
10.1182/blood-2018-04-843714
中图分类号
R5 [内科学];
学科分类号
100201 [内科学];
摘要
In classical Hodgkin lymphoma (cHL), the host antitumor immune response is ineffective. Hodgkin Reed-Sternberg (HRS) cells have multifaceted mechanisms to evade the immune system, including 9p24.1/CD274(PD-L1)/PDCD1LG2(PD-L2) genetic alterations, overexpression of PD-1 ligands, and associated T-cell exhaustion and additional structural bases of aberrant antigen presentation. The clinical success of PD-1 blockade in cHL suggests that the tumor microenvironment (TME) contains reversibly exhausted T effector cells (Teffs). However, durable responses are observed in patients with b2-microglobulin/major histocompatibility complex (MHC) class I loss on HRS cells, raising the possibility of non-CD81 T cell-mediated mechanisms of efficacy of PD-1 blockade. These observations highlight the need for a detailed analysis of the cHL TME. Using a customized time-of-flight mass cytometry panel, we simultaneously assessed cell suspensions from diagnostic cHL biopsies and control reactive lymph node/tonsil (RLNT) samples. Precise phenotyping of immune cell subsets revealed salient differences between cHLs and RLNTs. The TME in cHL is CD41 T-cell rich, with frequent loss of MHC class I expression on HRS cells. In cHLs, we found concomitant expansion of T helper 1 (Th1)-polarized Teffs and regulatory T cells (Tregs). The cHL Th1 Tregs expressed little or no PD-1, whereas the Th1 Teffs were PD-11. The differential PD-1 expression and likely functional Th1-polarized CD41 Tregs and exhausted Teffs may represent complementary mechanisms of immunosuppression in cHL.
引用
收藏
页码:825 / 836
页数:12
相关论文
共 58 条
[1]
AKBAR AN, 1988, J IMMUNOL, V140, P2171
[2]
Multiplexed ion beam imaging of human breast tumors [J].
Angelo, Michael ;
Bendall, Sean C. ;
Finck, Rachel ;
Hale, Matthew B. ;
Hitzman, Chuck ;
Borowsky, Alexander D. ;
Levenson, Richard M. ;
Lowe, John B. ;
Liu, Scot D. ;
Zhao, Shuchun ;
Natkunam, Yasodha ;
Nolan, Garry P. .
NATURE MEDICINE, 2014, 20 (04) :436-+
[3]
[Anonymous], 2017, CELL
[4]
PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma [J].
Ansell, Stephen M. ;
Lesokhin, Alexander M. ;
Borrello, Ivan ;
Halwani, Ahmad ;
Scott, Emma C. ;
Gutierrez, Martin ;
Schuster, Stephen J. ;
Millenson, Michael M. ;
Cattry, Deepika ;
Freeman, Gordon J. ;
Rodig, Scott J. ;
Chapuy, Bjoern ;
Ligon, Azra H. ;
Zhu, Lili ;
Grosso, Joseph F. ;
Kim, Su Young ;
Timmerman, John M. ;
Shipp, Margaret A. ;
Armand, Philippe .
NEW ENGLAND JOURNAL OF MEDICINE, 2015, 372 (04) :311-319
[5]
Nivolumab for Relapsed/Refractory Classic Hodgkin Lymphoma After Failure of Autologous Hematopoietic Cell Transplantation: Extended Follow-Up of the Multicohort Single-Arm Phase II CheckMate 205 Trial [J].
Armand, Philippe ;
Engert, Andreas ;
Younes, Anas ;
Fanale, Michelle ;
Santoro, Armando ;
Zinzani, Pier Luigi ;
Timmerman, John M. ;
Collins, Graham P. ;
Ramchandren, Radhakrishnan ;
Cohen, Jonathon B. ;
De Boer, Jan Paul ;
Kuruvilla, John ;
Savage, Kerry J. ;
Trneny, Marek ;
Shipp, Margaret A. ;
Kato, Kazunobu ;
Sumbul, Anne ;
Farsaci, Benedetto ;
Ansell, Stephen M. .
JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (14) :1428-+
[6]
Programmed Death-1 Blockade With Pembrolizumab in Patients With Classical Hodgkin Lymphoma After Brentuximab Vedotin Failure [J].
Armand, Philippe ;
Shipp, Margaret A. ;
Ribrag, Vincent ;
Michot, Jean-Marie ;
Zinzani, Pier Luigi ;
Kuruvilla, John ;
Snyder, Ellen S. ;
Ricart, Alejandro D. ;
Balakumaran, Arun ;
Rose, Shelonitda ;
Moskowitz, Craig H. .
JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (31) :3733-+
[7]
Macrophage Polarisation: an Immunohistochemical Approach for Identifying M1 and M2 Macrophages [J].
Barros, Mario Henrique M. ;
Hauck, Franziska ;
Dreyer, Johannes H. ;
Kempkes, Bettina ;
Niedobitek, Gerald .
PLOS ONE, 2013, 8 (11)
[8]
Selective expansion of a subset of exhausted CD8 T cells by αPD-L1 blockade [J].
Blackburn, Shawn D. ;
Shin, Haina ;
Freeman, Gordon J. ;
Wherry, E. John .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2008, 105 (39) :15016-15021
[9]
Topological analysis reveals a PD-L1-associated microenvironmental niche for Reed-Sternberg cells in Hodgkin lymphoma [J].
Carey, Christopher D. ;
Gusenleitner, Daniel ;
Lipschitz, Mikel ;
Roemer, Margaretha G. M. ;
Stack, Edward C. ;
Gjini, Evisa ;
Hu, Xihao ;
Redd, Robert ;
Freeman, Gordon J. ;
Neuberg, Donna ;
Hodi, F. Stephen ;
Liu, Xiaole Shirley ;
Shipp, Margaret A. ;
Rodig, Scott J. .
BLOOD, 2017, 130 (22) :2420-2430
[10]
Phase II Study of the Efficacy and Safety of Pembrolizumab for Relapsed/Refractory Classic Hodgkin Lymphoma [J].
Chen, Robert ;
Zinzani, Pier Luigi ;
Fanale, Michelle A. ;
Armand, Philippe ;
Johnson, Nathalie A. ;
Brice, Pauline ;
Radford, John ;
Ribrag, Vincent ;
Molin, Daniel ;
Vassilakopoulos, Theodoros P. ;
Tomita, Akihiro ;
von Tresckow, Bastian ;
Shipp, Margaret A. ;
Zhang, Yinghua ;
Ricart, Alejandro D. ;
Balakumaran, Arun ;
Moskowitz, Craig H. .
JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (19) :2125-+